Challenge
A European clinical-stage biopharma company was developing a recombinant protein for multiple immune-driven indications and required support in shaping its future business strategy. Alacrita was commissioned to conduct an independent strategic review of the company, identify any short and long-term value-adding activities for its programs and identify potential future pharma partners.
Solution
Alacrita's specialist team conducted a reality check on the target company's activities to date, analyzing the biological target robustness across different indications, proof of concept data from each program and the current valuation assumptions.
From this we identified several activities and direction changes that could add immediate value to the company and improve attractiveness to future pharma partners.
Our Strategy & Commercialization Support
Whether you need guidance charting your optimal path to market, technical or market insight to prioritize your R&D portfolio, or strategic support to help you best position your biotech or program for a fundraising round, we can assist.
Our consultants average 20-30 years of industry experience and bring significant first-hand knowledge to every project. Our core team leverages our Expert Network, which contains over 90 expert strategy and commercialization consultants who specialize in specific technologies and disease areas, allowing us to provide precisely relevant expertise across the below functional disciplines: